OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings, Inc. has announced the appointment of Dr. Andreas Niethammer as the new Chief Medical Officer of Vaximm AG, a subsidiary focused on innovative cancer therapies. The announcement was made on July 15, 2025, from both Basel, Switzerland, and Seoul, South Korea. Dr. Niethammer brings over two decades of experience in oncology and immunotherapy, positioning him to lead Vaximm’s clinical strategy effectively.
Dr. Niethammer, a recognized expert in cancer immunotherapy, previously held senior roles at major biopharmaceutical companies, including Fate Therapeutics and Pfizer. His extensive background includes significant contributions to the development of T-cell activators, notably VXM01, which targets VEGFR-2 and is currently in clinical trials. He co-founded Vaximm to advance oral T-cell vaccination methods based on his earlier research at the Scripps Research Institute.
Leadership Transition and Future Plans
Dr. Constance Höfer, Chief Science Officer of OSR Holdings, expressed enthusiasm for Dr. Niethammer’s return, emphasizing his unique insight into Vaximm’s foundational science. She stated, “His deep global clinical development experience perfectly positions him to continue advancing VXM01 and expand our oncology pipeline.”
In his statement, Dr. Niethammer highlighted the potential of Vaximm’s platform to improve treatment options for patients suffering from difficult-to-treat cancers. “With OSR Holdings’ resources, we are uniquely positioned to accelerate the development of powerful oral immunotherapies,” he noted. This ambition aligns with OSR Holdings’ vision of enhancing patient care through cutting-edge research.
Dr. Niethammer holds both an M.D. and a Ph.D. from the University of Heidelberg and is currently an associate professor of oncology at Heidelberg University. He has published extensively in peer-reviewed journals, establishing a reputation as a leader in T-cell-based cancer vaccine development.
About Vaximm AG and OSR Holdings
Vaximm AG, based in Switzerland and Germany, is dedicated to developing oral T-cell immunotherapies for cancer. Its lead program, VXM01, has successfully completed Phase I/II clinical trials targeting pancreatic cancer and glioblastoma. The company’s innovative approach aims to activate cytotoxic T-cell responses through oral administration, representing a significant advancement in cancer treatment.
OSR Holdings, Inc. operates as a global healthcare holding company and is listed on NASDAQ under the ticker OSRH. The company focuses on biomedical innovation to enhance health outcomes and operates in areas such as immuno-oncology and regenerative biologics. Its mission is to acquire and manage a portfolio of innovative healthcare companies, driving forward cutting-edge research and development to improve patient care.
As Vaximm continues to progress under Dr. Niethammer’s leadership, the company aims to redefine treatment options and improve outcomes for patients facing challenging health conditions.
